Our Challenges
Taiyo Pharma Co., Ltd. (hereafter, Taiyo Pharma) was established on August 2, 2017 as the wholly owned medical and pharmaceutical business subsidiary of Taiyo Holdings Co., Ltd. (hereafter, Taiyo Holdings). Our founding vision is to increase the Taiyo Group’s social contribution level and deliver pharmaceutical drugs to markets around the world. Since our founding, we have worked to solidify our corporate structure based on our primary mission of applying diverse technology towards providing patients with a stable supply of socially critical pharmaceutical drugs that have a long and established history of use. As a result of these efforts, in November 2017 we reached a consensus on agreements to transfers rights of long-listed products with Chugai Pharmaceutical Co., Ltd. and F. Hoffmann-La Roche Ltd. for 13 long-listed products. In line with taking over sales of these drugs, we are entering the phase of full-scale engagement in the pharmaceutical drugs industry. During this phase, we will establish a structure for the manufacturing and distribution of pharmaceutical drugs. Moving forward, as a business involved in the manufacture and sale of pharmaceutical drugs, we will strive to ensure comprehensive reliability in our business activities, protect the brand value of inherited products, and continue providing products and information to patients and medical professionals. To make this into the first step towards evolving into a comprehensive chemical company, the long-term vision for Taiyo Holdings, we will establish a firm foundation in the pharmaceutical drugs industry and grow into a business that transcends industry and international borders.
One of our core growth strategies will be the additional inheritance of long-listed products. At present, we have taken over 13 long-listed products from Chugai Pharmaceutical Co., Ltd and Hoffmann-La Roche Ltd. We will increase our portfolio of inherited products to respond to broad-based needs as a pharmaceutical company and increase sales. In addition to existing products, we will prioritize investments in plant acquisition and construction as we aim to increase our portfolio of products manufactured in-house. Simultaneously to manufacturing and sales, we also will work to improve revenues for long-listed products in order to improve profitability. To improve our pharmaceutical technology, we also will focus on establishing an R&D facility. To concentrate management resources on these core areas, for the time being we will refrain from engaging in drug creation and instead specialize on pharmaceutical developing and manufacturing long-listed products.
As soon as we establish our structure for manufacturing and sales in Japan, we will begin working on our global structure. We will apply the Taiyo Group’s knowledge and experience in global operations towards engaging in overseas markets. As a stepping stone, we are already conducting research towards engaging in East Asia, where the Taiyo Group has a strong business network. We will evaluate all available methods to engage in global markets, including market engagement via M&A activities. Specific plans will be drafted based on the results of careful market analysis. After establishing our position as a pharmaceutical company on global markets, we want to apply our cumulative knowhow and experience towards expanding into medical industries beyond pharmaceutical drugs such as medical technology and therapeutic medicine.
Lastly, we will partner with Group companies in other domains to establish ourselves firm contributor to the Taiyo Group vision of becoming a comprehensive chemical company.
Chairman of the Board and Representative Director
Auditor of Taiwan Taiyo Ink in 2001. Assumed role of director at Taiyo Holdings in 2008. Became executive officer and Group CFO in 2009. President and CEO since 2011. Assumed current role as Chairman of the Board and Representative Director of Taiyo Pharma in 2017.
Representative Director and COO
General Manager of Sales Division at Taiyo Ink Mfg. in 2014. After serving as General Manager of the R&D Dvision at Taiyo Holdings in 2015, assumed role of New Business Development Department Manager before becoming President and COO of Taiyo Pharma in 2017.
Director
Joined Taiyo Holdings in 2016. Assumed role of director at Taiyo Pharma in 2017, also serves as Reliability Assurance Department Manager.
Director
Joined Taiyo Holdings in 2016. Assumed role of director at Taiyo Pharma in 2017, also serves as Quality Assurance Department Manager.
Last update date February, 2019